LINC00410: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC00410

NCBI ID: G144776

LINC00410

Other Name(s): long intergenic non-protein coding RNA 410 | Long intergenic non-protein coding RNA 410

LINC00410: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC00410 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature of being located between the coding regions of two adjacent genes, which has led to its nickname as a \"contiguous non-protein-coding RNA.\" LINC00410 has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

Drug Target Potential

The potential drug targets for LINC00410 are numerous and varied. One of the primary drug targets for LINC00410 is its role in cell adhesion, which is critical for various physiological processes, including embryonic development, tissue repair, and cancer progression. LINC00410 has been shown to regulate the adhesion molecules E-cadherin and N-cadherin, which are involved in the formation of tight junctions and adherens junctions, which are essential for maintaining tissue structure and function.

Another potential drug target for LINC00410 is its role in cell migration. LINC00410 has been shown to be involved in the regulation of cell migration, including the migration of cancer cells to tumors. This is important because cancer cells are able to migrate to new sites and form new tumors, which is a major contributor to tumor progression and the development of invasive diseases.

Biomarker Potential

LINC00410 has also been identified as a potential biomarker for various diseases, including cancer. This is because its expression has been shown to be regulated in a variety of cancer types, including breast, ovarian, and prostate cancers. Additionally, LINC00410 has been shown to be involved in the regulation of cell cycle progression, which is a critical aspect of cancer development.

Methodology

To study the potential drug targets and biomarkers for LINC00410, researchers have used a variety of techniques, including RNA sequencing, qRT-PCR, and western blotting. These studies have led to several findings that suggest the potential of LINC00410 as a drug target and biomarker.

First, researchers have shown that LINC00410 is involved in the regulation of cell adhesion. This was demonstrated by the fact that LINC00410 is able to interact with the adhesion molecule E-cadherin and regulate its expression. Additionally, researchers have shown that LINC00410 is involved in the regulation of cell migration. This was demonstrated by the fact that LINC00410 is able to interact with the migration protein, Src, and regulate its expression.

Second, researchers have shown that LINC00410 is involved in the regulation of cell cycle progression. This was demonstrated by the fact that LINC00410 is able to interact with the cyclin D1 protein and regulate its stability.

Finally, researchers have shown that LINC00410 is involved in the regulation of various cellular processes, including cell adhesion, migration, and transcriptional regulation. This is consistent with its unique feature of being located between the coding regions of two adjacent genes, which has led to its nickname as a \"contiguous non-protein-coding RNA.\"

Conclusion

LINC00410 is a long intergenic non-protein-coding RNA that has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation. Its unique feature of being located between the coding regions of two adjacent genes has led to its nickname as a \"contiguous non-protein-coding RNA.\" Based on these findings, LINC00410 is a promising drug target and biomarker for a variety of diseases, including cancer. Further research is needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 410

The "LINC00410 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00410 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets